Cardiff University works on anthrax vaccine for NATO

Scientists from the U.K.'s Cardiff University are leading a NATO project to develop an anthrax vaccine. Researchers from the U.S., Turkey and the former Soviet republic of Georgia will work with the university to develop a vaccine that's more effective than the one currently available. The team hopes to work with individuals in Turkey and Georgia, where anthrax infection is a problem. Story

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.